NCT02833857View on ClinicalTrials.gov

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

March 14, 2017

Primary Completion Date

October 31, 2018

Study Completion Date

October 31, 2018

Conditions
Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions
DRUG

Etelcalcetide

A single IV-bolus dose of 0.035 mg/kg etelcalcetide into the venous line of the dialysis circuit at the end of a hemodialysis session.

Trial Locations (13)

1020

Research Site, Brussels

3000

Research Site, Leuven

9000

Research Site, Ghent

30625

Research Site, Hanover

35043

Research Site, Marburg

40202

Research Site, Louisville

50937

Research Site, Cologne

64108

Research Site, Kansas City

69120

Research Site, Heidelberg

90095

Research Site, Los Angeles

08406

Research Site, Vilinus

30-663

Research Site, Krakow

WC1N 3JH

Research Site, London

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02833857 - A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis | Biotech Hunter | Biotech Hunter